UniProtKB/Swiss-Prot Q9UQB3: Variant p.Gly275Cys

Catenin delta-2
Gene: CTNND2
Feedback?

Variant information Variant position:

275 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Cysteine (C) at position 275 (G275C, p.Gly275Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from glycine (G) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Found in patients with autism; uncertain significance; has no effect on Wnt signaling. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs61749844 [ dbSNP | Ensembl ]

Sequence information Variant position:

275 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

1225 The length of the canonical sequence.
Location on the sequence:

SSSTLPAPPRGGSPLAAPQG G SPTKLQRGGSAPEGATYAAP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SSSTLPAPPRGGSPLAAPQGGSPTKLQRGGSAPEGATYAAP

Mouse                         SSSTLPAPPRGGSPLTTTQGGSPTKLQRGGSAPEGAAYAAP

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 1225	Catenin delta-2
Region	256 – 312	Disordered
Modified residue	264 – 264	Omega-N-methylarginine
Modified residue	267 – 267	Phosphoserine
Modified residue	276 – 276	Phosphoserine
Modified residue	282 – 282	Omega-N-methylarginine

Literature citations
Submission
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS CYS-275; THR-482 AND ARG-810; Loss of delta-catenin function in severe autism.
Turner T.N.; Sharma K.; Oh E.C.; Liu Y.P.; Collins R.L.; Sosa M.X.; Auer D.R.; Brand H.; Sanders S.J.; Moreno-De-Luca D.; Pihur V.; Plona T.; Pike K.; Soppet D.R.; Smith M.W.; Cheung S.W.; Martin C.L.; State M.W.; Talkowski M.E.; Cook E.; Huganir R.; Katsanis N.; Chakravarti A.;
Nature 520:51-56(2015)
Cited for: FUNCTION; TISSUE SPECIFICITY; INTERACTION WITH CTNNB1; INVOLVEMENT IN AUTISM; VARIANTS SER-34; LEU-189; LEU-224; CYS-275; HIS-330; HIS-454; ASN-465; THR-482; PRO-507; CYS-713 AND MET-862; CHARACTERIZATION OF VARIANTS SER-34; LEU-189; LEU-224; CYS-275; HIS-330; HIS-454; ASN-465; THR-482; PRO-507; CYS-713; ARG-810 AND MET-862;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.